These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 30589970

  • 1. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G.
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [Abstract] [Full Text] [Related]

  • 2. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 3. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A, Straathof JW, Derijks LJ.
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [Abstract] [Full Text] [Related]

  • 5. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
    Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T.
    Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases.
    Petitcollin A, Brochard C, Siproudhis L, Tron C, Verdier MC, Lemaitre F, Lucidarme C, Bouguen G, Bellissant É.
    Clin Pharmacol Ther; 2019 Sep; 106(3):605-615. PubMed ID: 30860594
    [Abstract] [Full Text] [Related]

  • 7. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y, Farcet JP, Delchier JC, Hüe S.
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review.
    Little DHW, Tabatabavakili S, Shaffer SR, Nguyen GC, Weizman AV, Targownik LE.
    Am J Gastroenterol; 2020 Nov; 115(11):1768-1774. PubMed ID: 33156094
    [Abstract] [Full Text] [Related]

  • 10. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study.
    Srinivasan A, van Langenberg D, De Cruz P, Segal J, Vasudevan A, Upton RN.
    BioDrugs; 2024 Sep; 38(5):691-702. PubMed ID: 39168947
    [Abstract] [Full Text] [Related]

  • 11. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN.
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [Abstract] [Full Text] [Related]

  • 12. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A, Batovsky M, Gregus M, Hlista M, Durina J, Leskova Z, Sturdik I, Gojdic M, Jalali Y, Koller T, Toth J, Huorka M, Hlavaty T.
    Acta Gastroenterol Belg; 2018 Oct; 81(4):465-470. PubMed ID: 30645913
    [Abstract] [Full Text] [Related]

  • 13. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S.
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [Abstract] [Full Text] [Related]

  • 14. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Crohns Colitis; 2018 Nov 15; 12(11):1316-1325. PubMed ID: 30239644
    [Abstract] [Full Text] [Related]

  • 15. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL.
    Eur J Gastroenterol Hepatol; 2018 Jul 15; 30(7):699-703. PubMed ID: 29538037
    [Abstract] [Full Text] [Related]

  • 16. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D, GETAID.
    Gastroenterology; 2018 Apr 15; 154(5):1343-1351.e1. PubMed ID: 29317275
    [Abstract] [Full Text] [Related]

  • 17. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
    Little RD, Chu IE, Ward MG, Sparrow MP.
    Dig Dis Sci; 2022 Jan 15; 67(1):259-262. PubMed ID: 33763785
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS.
    Clin Gastroenterol Hepatol; 2017 Oct 15; 15(10):1580-1588.e3. PubMed ID: 28365486
    [Abstract] [Full Text] [Related]

  • 20. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S, Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, Dreesen E, D'Haens G, Dervieux T, Laharie D.
    Clin Res Hepatol Gastroenterol; 2024 Jun 15; 48(6):102374. PubMed ID: 38750934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.